INJEX Pharma AG
INJEX Pharma AG: Strategic Investor intents to invest in INJEX Pharma AG
INJEX Pharma AG / Key word(s): Miscellaneous 10.12.2013 14:55 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad hoc: Strategic Investor intents to invest in INJEX Pharma AG Berlin, December 10, 2013 - INJEX Pharma AG announces, that a term sheet has been signed with a strategic financial investor to provide the short-term liquidity to the company needed to continue its operations. The term sheet provides that the financial investor subscribes all newly issued INJEX Pharma ordinary shares in a 10% capital increase. The shares will be issued via private placement without pre-emptive rights. Furthermore, the new investor will acquire shares from MMB Medical Marketing Berlin GmbH (MMB), the major shareholder of INJEX Pharma AG. MMB will then transfer almost the entire sales proceeds as a shareholder loan to INJEX Pharma AG. The goal is to complete the transaction within the next days to provide the short-term needed liquidity to the company. This transaction is an important step to shape the company for the future. For further information on INJEX Pharma AG and its subsidiaries, please refer to www.injex.com. For further questions please contact our Investor Relations team directly: INJEX Pharma AG Investor Relations-Team t: +49 89 24 41 18 - 223 f: +49 89 24 41 18 - 228 ir@injex.de INJEX Pharma AG: INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and INJEX Vertrieb Deutschland GmbH are specialized in the development, manufacturing and marketing in the medical technology segment and in the cosmetics and beauty markets. The Group's core business areas are the needle-free INJEX30 system and the product line SHIREEN in the beauty market. The main markets of the Group are North America, China, India, Russia and Europe. 10.12.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: INJEX Pharma AG Buckower Damm 114 12349 Berlin Germany Phone: +49 89 24 41 18 - 223 Fax: +49 89 24 41 18 - 499 E-mail: ir@injex.de Internet: www.injex.de ISIN: DE000A0STYL7 WKN: A0STYL Listed: Regulierter Markt in Frankfurt (General Standard) Notierung im Regulierten Markt vorgesehen / intended to be listed at Regulated Market End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found